Tudor Investment Corp ET AL Raises Holdings in uniQure (NASDAQ:QURE)

Tudor Investment Corp ET AL lifted its position in uniQure (NASDAQ:QURE) by 5.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,784 shares of the biotechnology company’s stock after purchasing an additional 1,371 shares during the quarter. Tudor Investment Corp ET AL’s holdings in uniQure were worth $438,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Avoro Capital Advisors LLC bought a new stake in uniQure in the 4th quarter worth approximately $38,410,000. Franklin Resources Inc. bought a new stake in uniQure in the third quarter worth $7,360,000. Invesco Ltd. raised its stake in uniQure by 453.2% during the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company’s stock valued at $10,836,000 after purchasing an additional 502,684 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in uniQure during the fourth quarter valued at $5,553,000. Finally, Trexquant Investment LP purchased a new position in shares of uniQure in the 4th quarter worth $2,527,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on QURE shares. Royal Bank of Canada restated an “outperform” rating and set a $24.00 target price on shares of uniQure in a research report on Tuesday, January 21st. Chardan Capital reiterated a “buy” rating and issued a $38.00 target price on shares of uniQure in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Monday, April 21st. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Tuesday, March 11th. Finally, Wells Fargo & Company cut their price objective on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.80.

uniQure Stock Up 21.8 %

NASDAQ:QURE opened at $12.25 on Friday. The company has a market cap of $671.01 million, a price-to-earnings ratio of -2.47 and a beta of 0.10. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a fifty day simple moving average of $12.19 and a 200-day simple moving average of $12.01.

Insider Activity at uniQure

In other news, CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 6,717 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the sale, the chief executive officer now owns 580,795 shares of the company’s stock, valued at $6,574,599.40. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock worth $961,401 in the last 90 days. 4.74% of the stock is owned by corporate insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.